

2022 Series



**LIFE SCIENCE
NATION**

Connecting Products, Services & Capital

DIGITAL SPONSORSHIP BROCHURE



RESI REDEFINING
EARLY STAGE
INVESTMENTS

DIGITAL RESI JPM, JANUARY 11-13

DIGITAL RESI, MARCH 22-24

RESI SAN DIEGO, JUNE 14-16

RESI BOSTON, SEPTEMBER 20-22

RESI ASIA, NOVEMBER 15-17

NEXT



CONTENTS

3

Why Sponsor?

4

Conferences

4. Attendee Demographics

5. Standard Partnering

6. Premier Partnering

7

Who Sponsors?

8

Sponsorship Levels

9

Sponsorship Branding

9. Dedicated Webpage

10. Logo Features

11. Newsletter Article & Banner Ad

12. Panels & Workshops

13. Innovator's Pitch Challenge

◀ **BACK**

NEXT ▶

Why Sponsor?

Sponsorship can help your company gain unprecedented visibility into the early-stage life science community, and leverage Life Science Nation (LSN)'s close-knit network of key decision-makers to make promising connections with future clients and strategic partners. Each sponsorship offering is designed to:

- Help organizations increase global exposure through high visibility branding and messaging
- Target and source assets and strategic partnerships
- Advertise products and services through programming
- Network with industry leaders

Sponsorship Benefits

1

Increase global brand and reach:

- Participate in RESI Partnering Week (16K annual attendance)
- Be featured in the Next Phase Newsletter (48K weekly readership)

2

Source, vet, and develop key relationships with your target audience:

- Tech Hubs – Feature your constituents
- Investors – Add quality companies to your portfolio
- Service Providers – Increase your deal pipeline and access to investor portfolios

3

Access post-event attendee list, including:

- Start-up Companies
- Service Providers
- Investors
- Government Agencies
- Tech HubsF

4

Showcase your product and services:

- Moderate an expert panel
- Host and deliver a workshop

5

Use our one-of-a-kind match-based partnering platform to connect with strategic partners and build relationships

Attendee Demographics

In the past **10** years, **300+** companies have raised **\$400M+** through **35+** RESI conferences.



1,000+
Participating Attendees


2,500-3500+
Virtual Partnering Meetings


Participants from **30+** Countries


72 hours of uninterrupted partnering

Global Attendees



■ North-America ■ Europe ■ Asia

Attendee Profiles

Venture Capital	43%
Angels & Family Office	17%
Big Pharma & Medtech	15%
Corporate Venture Capital	14%
Private Equity	5%
Endowments & Foundations	3%
Government Organizations	3%



Startup

Therapeutics	50%
Medical Device	32%
Diagnostics	13%
Digital Health	5%

46%

Investor



38%

16%



Service Provider & Others

Service Provider	58%
Tech Hub & Incubator	14%
Non-Profit	13%
IBanks & R&D Services	7%
Regional Organization	5%
Media & Other	4%

◀ BACK

NEXT ▶

Standard Partnering

Partnering Overview Partnering is one of the most valuable facets of LSN conferences. The partnering platform is designed to match attendees based on sector, indication, phase of development, etc. (see below to see criteria), eliminating the question, “Is this a good fit for my needs?” Fundraising companies match with a diverse pool of investors who fit both development stage and product set. Investors and strategic partners can explore the latest innovation in a format that easily connects them with products they are most interested in. Sponsors, exhibitors, and providers also can review attendee profiles to find the best fit for their services


How Does it Work? Partnering opens two weeks before the conference, providing time to upload personal schedules and company profiles, as well as review and request meetings using the filters based on which attendees you are most interested in meeting. LSN hosts free workshops to review platform function and provide tips for anyone who is new or inexperienced with partnering events. Click below to view a partnering tutorial.



LIFE SCIENCE NATION
Connecting Products, Services & Capital

Digital RESI Partnering Tutorial

Greg Mannix
Chief Conference Officer, VP of Global Business Development
g.mannix@lifesciencenation.com



The screenshot displays the LSN Partnering Platform interface. At the top, there is a navigation bar with links for Home, Search, Sessions, Messages, Schedule, and Account. Below this is a search bar with the text "Start searching..." and a "Search" button. The main content area shows search results for "1984 Ventures" and "3E Bioventures". On the left side, there is a sidebar with filters for Groups, Investor Type, Main Sector, Indications, Biotech Phase of Development, Medtech/Diagnostic Phase of Development, Capital Structure Preference, and Investment Stage Preference. Callout boxes highlight specific filter options: Investor Type (Venture Capital), Main Sector (Biotech Therapeutics, Biotechnology Other, Biotechnology R&D Services, Diagnostics, Healthcare IT, Medical Technology, Supplier & Engineering), Therapeutic Product Development Phase (NDA, Phase I, Phase II, Phase III, Pre-Clinical), Medtech/Diagnostic Development Phase (Clinical, In Development, On the Market), Orphan Interest? (No), Capital Structure Preference (Equity), Investment Stage (Growth, Seed, Venture), and Year Founded (2017).

Premier Partnering

The **Standard partnering profile** provides filterable information about each investor's sector(s), indications(s) and phase(s) of development they seek. Attendees reviewing a standard profile can judge if they are a fit for their product offerings. Standard profiles contain:

- Allocation Information
- Investor Type
- Main Sector
- Indications
- Phase of Development
- Orphan Interest
- Capital Structure Preference
- Investment Stage
- Attending Investors
- "Book Meetings" Option

A **Premier partnering profile** provides exclusive access to full investor mandates, imported from LSN's database with 5,000+ profiles, including personal contact information for each investor. This information is gathered by LSN's investor research team, based on annual conversations and updates provided through one-on-one updates. Attendees can upgrade their standard profile to premier for an additional \$500.

Premier Partnering Only Content

- Access to Investor Mandates
- Direct Contact Email
- Sectors and Sub-Sectors of Interest
- Company & Management Team Requirements

6 Dimensions Capital

Allocation Information

6 Dimensions Capital is a healthcare-focused venture capital firm formed in 2017 through the merger of Frontline BioVentures and WuXi Healthcare Ventures. Frontline BioVentures manages 2 funds, a RMB denominated fund and a parallel USD fund. WuXi Healthcare Ventures manages its \$250 million Fund II, with WuXi PharmaTech being the anchor. The firm generally seeks to make equity investments into emerging life science companies in seed and venture stages; however, the fund also considers commercial-stage companies, depending on the opportunity. The investment size of the USD fund ranges from \$5 - \$25 million. For the RMB fund, typical investment size is RMB 30- RMB150 million. The firm currently focuses on China-based companies or overseas businesses with a China angle.

Sectors and Subsectors of Interest

6 Dimensions Capital is looking for new investment opportunities across a wide spectrum of life science sectors, including Therapeutics, Diagnostics, Biotech R&D Services, Medical Technology and Healthcare IT. The firm is agnostic to disease indications but is most interested in areas with large market potential, including Diabetes, Cardiovascular, Musculoskeletal System and Connective Tissue. Diseases of the Eye and Oncology. Rare diseases are generally less of interest. The firm is open to invest in both small molecules and biologics, and it looks for all classes of devices. The funds are most interested in companies in preclinical and early-clinical stage, but they are open to companies in late-clinical and growth stage, on a case-by-case basis.

Company and Management Team Requirements

6 Dimensions Capital will only invest in private companies. The firm is looking to be an active investor, sometimes taking a board seat post-investment.

Investor Type

Venture Capital

Main Sector

- Biotech Therapeutics
- Biotechnology Other
- Biotechnology R&D Services
- Diagnostics
- Healthcare IT
- Medical Technology
- Supplier & Engineering

Indications

- Blood Diseases/Immune Disorders
- Cardiovascular
- Cond. Orig. in the Prenatal Period
- Congen. Deform. & Chrom. Defects
- Digestive System
- Diseases of the Ear
- Diseases of the Eye
- Diseases of the Nervous System
- Endocrine/Nutri/Metabolic Dis.
- Ext. Causes of Morbidity & Mortality
- Genitourinary System
- Infectious and Parasitic Diseases
- Mental and Behavioral Disorders
- Musculoskeletal System & Connect. Tiss.
- Neoplasms/Cancer/Oncology
- Other
- Pain and Inflammation
- Physical Injury/Poisoning
- Pregnancy/Childbirth & Puerperium
- Respiratory
- Skin and Subcutaneous Tissue

Therapeutic Product Development Phase

- NDA
- Phase I
- Phase II
- Phase III
- Pre-Clinical

Medtech/Diagnostic Development Phase

- Clinical
- In Development
- On the Market

Orphan Interest?

No

Capital Structure Preference

- Equity

Investment Stage

- Growth
- Seed
- Venture

Year Founded

2017

Direct Contact Email

Executive Director
Contact Email

Click To Request a Meeting

<https://digital-res-sept.meeting-mqo.com/search?id=314001>

Who Sponsors?

Service providers selling their services to funded CEOs, establishing relationships with global strategic partners and expanding market presence

Global investors, channel partners, strategic partners and big pharma sourcing technology assets for their pipeline, channels and new silos

Regional tech hubs, accelerators and incubators, government entities, non-profit groups and foundations introducing and showcasing their constituents to the global marketplace

Investors expanding their portfolio through technology assets, finding investment partners for joint deal syndication, and finding service providers to help develop their portfolio



Past RESI Sponsors



◀ BACK

NEXT ▶

Sponsorship Levels & Bundles

	Co-Organizer*	Title*	Gold*	Silver	Bronze	Ad. Sponsor	Service Provider Showcase
Dedicated Webpage	✓	✓	✓	✓	✓		✓
Logo Feature (Website)	✓	✓	✓	✓	✓	✓	✓
Logo Feature (Track)	✓	✓					
Logo Feature (Banner)	✓	✓					
Free Registration	6	6	5	4	3		
Discounted Registration	25%	25%	20%	15%	10%		
Newsletter Article	✓	✓	✓	✓		✓	
Newsletter Banner Ad	3	3	2	1	1	✓	
Workshop or Panel	✓	✓	✓	✓			✓
Post-Event Attendee List	✓	✓	✓	✓			
Post-Event Attendee Contact Information	✓	✓	✓				
Regional Partner	✓						

Price **\$150K** **\$25K** **\$15K** **\$10K** **\$5K** **\$2K** **\$1.5K**

**Innovator's Pitch Challenge (IPC) sessions available at an additional fee.*

[View IPC Page for Details](#)

Sponsorship Bundles

Bundle	Offer
Sponsor 2 Events	Get the 3 rd 15% Off
Sponsor 3 Events	Get the 4 th 25% Off

Sponsors may bundle event deals for maximum savings and increased exposure across the early-stage arena within life science and healthcare. Organizations may sponsor two events at equal levels and receive the same level to a third event at a 15% discount. Additionally, they may sponsor three events at the same level, and receive the same level to a fourth event at a 25% discount.


◀ **BACK**

NEXT ▶


Dedicated Webpage

Sponsors (except Ad. Sponsor) are provided a dedicated webpage that serves as their virtual exhibition booth. By clicking the sponsor's logo on the event Live Agenda, attendees gain access to their dedicated webpage, which hosts materials which can include, but are not limited to: video presentations, company description, team bios, and downloadable materials.


Title Sponsor






Gold Sponsor










Silver Sponsor




Featured Tech H



Media Part




Sponsor



Created in 1979 by the healthcare technology industry, Medmarc's mission is to be the superior provider of liability insurance protection and related risk management solutions to the medical technology industry. We support the development, testing, and delivery of medical products that save lives and improve the quality of life. Through collaboration with our parent company, ProAssurance, and our strategic alliance carriers in the U.S. and abroad, we provide a single source of innovative healthcare liability insurance solutions to the life sciences companies we serve. From ideas and prototypes to the reality of commercialization and success - We Can Meet Your Changing Needs. Contact us to learn more about the types of insurance coverage and what coverages are needed for your business plan. (703) 652-1360


Twitter Facebook LinkedIn

Medmarc 40th Testimonial Video



HEATHER THOMPSON
Chairman, Board Member
Medmarc Insurance Group

Pitch Deck



Lynn Carney
MEDMARC
Treated Fairly
A ProAssurance Company
Digital RESI

Claims Case Study

Light Therapy Device

Medmarc Defense Team Prevails in a Case Against a Light Therapy Device Manufacturer

EXECUTIVE SUMMARY
The plaintiff is this case, a defendant government, creating from burns left by an internet public light (PL) device manufactured by Medmarc's insured, PL Therapy Manufacturer (Defendant). The plaintiff presented multiple negligence claims, as well as claims for products liability. The plaintiff demanded a jury trial and \$12 million in damages. Medmarc's insured successfully avoided a jury trial and \$12 million in damages. Medmarc paid the amount of its deductible.

THE ALLEGATION
The plaintiff's case was complicated, involving the following claims:
• Negligent supervision, for PL Therapy's failure to properly supervise its employees, who failed to protect the plaintiff from burns.
• Negligent supervision, for PL Therapy's employment of the device to the medical use.
• Negligent supervision, for the defendant's failure to warn the medical use (off of risks associated with the device use, as well as to ensure device users received proper training.
• Lack of informed consent.

THE MANUFACTURER & THE PRODUCT
PL Therapy Manufacturer manufactures devices for medical and consumer applications. The device is used to provide PL therapy, a technology that treats wrinkles, skin damage, and acne. PL Therapy Manufacturer also manufactures companion hardware for face, hand, and body applications.

THE INCIDENT
The plaintiff was the subject in a training event hosted by PL Therapy Manufacturer at a medical spa. The plaintiff agreed to receive PL therapy during the training.

The full case number: 2013-04-0886
4795 Mainway Wood Lane, Suite 375 West
Chandler, AZ 85226-2219

Negligence Claim Based on Design Defect

Seasoned Experts, Swift Action Led to a Defense Verdict for Medmarc Insured

EXECUTIVE SUMMARY:
The owner of a medical center center rack suffered severe injuries in a vehicle collision when her scooter fell off the center rack and onto a highway while attempting to remove the scooter. The plaintiff attempted \$2.5 million in damages in a negligence claim. The jury found the scooter manufacturer and liable on all claims.

THE ALLEGATION
Smith alleged multiple negligence claims based on design defect against Medmarc's insured, ScooterChk, Inc., as well as against the center rack manufacturer and seller. Although Smith sued the center rack manufacturer and seller, she alleged the center was poorly designed because it lacked a warning system to alert users when it did not have sufficient energy or reporting problems about improperly secured scooters.

DAMAGES
Smith's medical bills totaled nearly \$700,000. Her lawsuit demanded \$2.5 million in damages.

THE LEGAL PROCEEDINGS
In this case, Medmarc's insured attorney representing ScooterChk, Inc. brought to light the following facts in Smith's case:
• ScooterChk, Inc. designed, distributed, and sold the center rack.
• ScooterChk, Inc. distributed, but did not manufacture, the center rack. Medmarc's insured attorney argued that ScooterChk, Inc. had no input in the center's design or manufacture.

The full case number: 2013-04-0886
4795 Mainway Wood Lane, Suite 375 West
Chandler, AZ 85226-2219

Dedicated Page Example

Ask us about the Service Provider Showcase options!


BACK

NEXT

Logo Features

Website


LSN event websites are the centralized locations for potential and registered attendees to access news and content related to the conference, making them the most prominent display for sponsoring company logos.



Track

Sponsors can customize track themes, or simply have a prominent logo feature. Examples differ based on whether track includes partnering, panel, workshop, or Innovator's Pitch Challenge.

Partnering: The sponsor's logo will be featured in the partnering system, which all attendees access. Additionally, all sponsor attendees will have premier partnering access for free while being featured as the partnering sponsor.




Banner

Event banners are used for promotion in a myriad of ways, including social media, email signatures, weekly newsletters, registration form, panel application, partnering platform, etc.



Panel or Workshop: The sponsor can plan topics for panel discussions or educational workshop, source speakers, and provide additional materials.



Innovator's Pitch Challenge:

The sponsor can set specific requirements and winner prizes, including services, products, cash, etc. Sponsors will also have access to review and select applications.



◀ BACK

NEXT ▶

Newsletter Article & Banner Ad

LSN's three weekly newsletters, Next Phase, The Mandate, and Age-Tech Bulletin, arrive in 50K inboxes each week, providing hot investor mandates, insightful articles, promotional news, or access to pre-recorded educational content. Sponsor banners run for three weeks which may include: company/event name, one tagline, and embedded link to the sponsor's website.

Article with content provided by sponsor, usually with the goal to educate or provide insight while promoting products and/or services

Life Science Nation Newsletter | February 27, 2020 | Issue 357

LIFE SCIENCE NATION
Connecting Products, Services & Capital

NEXT PHASE

The LSN Story | Investor Platform | Company Platform | RESI Conference | Fundraising Consulting

HOT Life Science Investor Mandates (Feb. 20 - Feb. 26)

Europe Venture Capital
Raises New Fund for Early Stage Drugs and Platforms

Asia Life Science Fund
Looking Globally for New Investments

Global Insurance Giant

NIH Is Supporting Entrepreneurs To Address The Looming Public Health Crisis
- Life Science Nation Chief, Office of Small on Aging, National Ins

Medmarc Insurance
We insure medical Innovation
Insuring the Life Sciences Industry Since 1979
Products Liability | Clinical Trials Liability | Manufacturers E&O
LEARN MORE >>

RESI REDEFINING EARLY STAGE INVESTMENTS
Created & Produced by **LIFE SCIENCE NATION**
Connecting Products, Services & Capital

Sponsor articles appear in one of two formats:

VIVA Biotech, Shanghai, China based CRO will be the Innovation Challenge Gold Sponsor for RESI

By Candice He, Global Investment Strategist, LSN



After supporting the RESI Conference Series with delegates and speakers for many years, VIVA Biotech has become a Gold Sponsor of RESI Shanghai and RESI San Francisco. At RESI, you will be able to meet with VIVA's expert speakers representing VIVA at RESI's panels and pitch sessions. You will also have the opportunity to meet with VIVA during RESI's cocktail party, where VIVA will present the awards for the RESI Innovation Challenge! Finally, RESI Shanghai attendees will also have the opportunity to take a tour of VIVA Biotech's incubator. We hope you will join us and our sponsors and partners at RESI Shanghai.

About VIVA Biotech



VIVA Biotech's mission is to become a cradle for innovative biotechnology companies around the world. VIVA Biotech has developed a scalable business model combining the conventional cash-for-service (CFS) model and its unique equity-for-service (EFS) model. Under the CFS model, the Group provides structure-based drug discovery services to its biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development, covering the full spectrum of the customers' needs for early stage drug discovery, including target protein expression and structure research, hit screening, lead optimization and drug candidate determination. VIVA Biotech also provides drug discovery and incubation services to biotechnology start-up companies with high potential under its EFS model. As of June 30, 2019, VIVA Biotech had provided drug discovery services to 388 biotechnology and pharmaceutical customers worldwide, worked on over 1,000 independent drug targets, delivered over 11,000 independent protein structures, and incubated a total of 37 early stage R&D projects.

Interview with M2D2: How Global Tech Hubs Showcase Startups to Investors at RESI



An interview with Mary Ann Picard, COO of the M2D2 Incubator

- By Greg Mannix, VP of International Business Development, LSN



Greg Mannix

One of the clear trends in Life Science funding is that investors are taking a keen interest in earlier and earlier-stage companies. Some investors will put money in at a very early stage, while others will come in a bit later, but what is very clear is that they all want to identify the most significant new technology breakthroughs in the life sciences and put those companies on their radar as soon as possible.

A majority of these hot, early-stage technologies are being developed in tech hubs all around the world. The Redefining Early-Stage Investments (RESI) conference series is an excellent opportunity for these Tech Hubs to gain visibility among investors who will want to track the technologies being incubated and accelerated in their facilities. This is why at LSN we have made a purposeful effort to create a nexus between these two key players in the life science ecosystem.

I recently spoke to Mary Ann Picard, COO of Massachusetts Medical Device Development (M2D2) Center about how RESI plays a part in the success of her program and its constituent companies.

Greg Mannix: First of all, I consider M2D2 a perfect example of a Tech Hub. Could you give me some context as to what M2D2 is?

Mary Ann Picard: M2D2 is an incubator program for medical device and biotech early stage startup companies. M2D2 is a joint project with UMass Lowell and UMass Medical School. No affiliation with UMass is required and no equity taken. Resident companies have access to a whole host of university

Banner Ad in Newsletter

Sponsor interview conducted and written by LSN's editorial team

Previous Issues

NEXT PHASE

THE MANDATE

AGE-TECH BULLETIN

◀ BACK

NEXT ▶

Panels & Workshops

Panels can be live or pre-recorded and are available for viewing online via the event website. These 50-minute discussions feature four panelists and one moderator, made up of active investors, strategic partners, and key industry leaders, with a diverse range of topics focused on the early-stage life science ecosystem. Sponsors may join a panel as a moderator with a 10-minute dedicated presentation for promotion.

Panels

In order to provide maximum value, LSN goes beyond partnering with expert panels and industry workshops – each designed with the early-stage player in mind – and available to help sponsors reach their goals.

Workshops

Workshops are sponsored webinars designed to educate leaders of fundraising companies on elements of the early-stage landscape often overlooked, which can include patents, recruitment, intellectual property, insurance, financial management, and so much more. Sponsors may host a dedicated workshop to promote brand, service, or product.

Recorded Live Panel

RESI REDEFINING EARLY STAGE INVESTMENTS
JUNE 8-10, 2021

Panels Workshops Attendees Partnering Pitch Challenge Sponsors RESI

Investor & Strategic Channel Partner Panels

The virtual panels at RESI take place March 15-17. Each panel will last for an hour and will be conducted through Zoom Webinar. Each panel will feature four panelists and one moderator, made up of active investors, strategic partners, corporations, etc. within life sciences and healthcare, including therapeutics, medical devices, and digital health.

Attendees will have an opportunity to ask questions via the Q&A feature in Zoom. The RESI team is available to facilitate connections between participating investors after the session.

For more information on each panel, please click on the titles below.

Panel Title	Time	Watch Playback
EARLY STAGE THERAPEUTICS Bringing the Newest Therapies to the Clinic	March 15, 10:00AM – 11:00AM	Watch Playback
MEDICAL DEVICE INVESTORS Investing in Novel Engineering	March 15, 02:00PM – 03:00PM	Watch Playback
DIGITAL THERAPEUTICS Novel Therapeutic Solutions Using Digital Technology	March 15, 04:00PM – 05:00PM	Watch Playback
COMBINATION DEVICES Integrated Devices That Cross Sector Boundaries	March 16, 02:00PM – 03:00PM	Watch Playback
CELL & GENE THERAPY The Next Generation of Therapeutic Technologies	March 16, 04:00PM – 05:00PM	Watch Playback
TOOLS AND R&D SERVICES Investing in the newest tools to advance research	March 17, 10:00AM – 11:00AM	Watch Playback
INVESTORS Leveraging Software to Lower Costs and Improve the Quality of Care	March 17, 02:00PM – 03:00PM	Watch Playback

Live Agenda

RESI REDEFINING EARLY STAGE INVESTMENTS
JUNE 8-10, 2021

CELL & GENE THERAPY

The Next Generation of Therapeutic Technologies

This panel focuses on the advent of gene & cell therapies that are now entering the market, from CRISPR to CAR-T antibodies, and how these new technologies are changing the paradigm of therapeutic development.

- Which of the technologies is the most compelling?
- What do investors do with these new techs?
- Even with how new it is, already becoming so.

Panelists will discuss how blockbuster drugs to some manufacturing challenges these new challenges are.

Panelists:

Fabio D'Agostino, Venture Partner, Claris Ventures (Moderator)

Fabio is a well-rounded life science consultant with over 9 years of experience in the industry. In 2013, he joined the Pharmaceutical Drug Association (PDA) and led Novartis, Lonza, Johnson & Johnson, Adaptimmune, Takeda, Bluebird bio, and other cell and gene based medicinal products. His areas of expertise are in the development and optimization, business development and technology transfer of early stage companies. He moved to Newcastle UoC to take an Engineering Doctorate (EngD) in 2018. One of his main projects was the Multifactorial Analysis of Transport.

Respect & Meeting

Panel Page

RESI REDEFINING EARLY STAGE INVESTMENTS

16:57 / 00:15




Ask us about the Service Provider Showcase options!

BACK

NEXT

Innovator's Pitch Challenge

Gold and Title Sponsors, as well as **Co-Organizers** can sponsor pitch sessions during the Innovator's Pitch Challenge. Investors sourcing quality deal flow or looking to boost portfolio visibility and service providers raising brand recognition among potential early-stage clients can also take advantage of the Innovator's Pitch Challenge as an excellent occasion to achieve these goals.



Live Q&A Session

Each session hosts five pitching companies who field questions from a live panel of investors. The price of sponsorship is \$5,000 USD per session. The following support options are available:

1 LSN calls for applications, scores the applications using a proprietary expert system, and selects the top five companies to participate in the pitch session. A panel of focused investors will be selected for the live session.

2 Sponsors select five companies to be showcased, and LSN recruits the panel of expert investors.

← BACK



» Back to LIVE Agenda

Innovator's Pitch Challenge

Vote for us



Interested in Connecting? Please contact:
Thomas Forest Farbi-Horch
CEO

Message the company or request a 1:1 meeting here.

Thrive is commercializing a family of instruments and software that provide previously unavailable data, imaging, analytics, and automation for cell culture, stem cell culture, and tissue culture for use in biomedical research and cell therapeutics. Thrive has recently started selling the first two instruments in the family, the CellAssist and the CellAssist 50. Both collect 1,000's of images of live cells in culture, analyze them, provides guidance and builds a significant database. The CellAssist 50 enables researchers to automatically and remotely image 50 plates of cells on an ongoing basis, generating large amounts of data for live cell biology. Sites include Harvard Stem Cell Institute, Center for Genomic Medicine (Massachusetts General Hospital), Stanford Stem Cell Core, University of Texas Medical Branch, as well as large and small pharma/biotech companies.

Pitch Video

Thrive's Solution — Family of Cell Culture Instruments & Software

- Integrates imaging, robotics, analytics & machine learning
- Common database, image processing, & modules across products
- Full ETL clearance or approval required

CellAssist (in Market)	CellAssist 50 (Early Access)	Software Modules (2021-2023)	Cell Culture System (Available 2023)
Remote imaging & analytics (single platform)	Automated 24/7 Cell Culture	<ul style="list-style-type: none"> Real-time Problem Solving in Cell Culture Real-time Process Control & Optimization Stem Cell Differentiation, Directional Monitoring Single Cell Tracking 	High-capacity intelligent 100 plate cell culture

Slide Deck

Thrive Bioscience
Analytics, Automation, Better Biology.

Overview of Company & Products

THRIVE BIOSCIENCE

"Top Biotech Growing Companies of 2020" — Venture Beat
"Top Biotech Companies of 2020" — Entrepreneur

Executive Summary

Thrive Bioscience, Inc.
Imaging, Analytics, and Automation for Cell Culture

Instruments and software
providing more data and the right data for cell biology.

The Need — Productivity in Research & Drug Discovery

Even though cell culture is at the center of biomedical research, it is:

- Difficult to master in 20+ years with limited automation
- Frequent mislabeling, contamination and process drift from the intended design
- Lacks reproducibility, resulting in experiments needing to be repeated
- Lacks documentation and data collection

The Solution — Thrive's Product Family

CellAssist (in Market) | CellAssist 50 (Early Access) | Full Automation (Available 2023)

Thrive's systems increase the efficiency and effectiveness of various manual and culture processes. More importantly, Thrive's products enable improved representation and provide previously unavailable data, analysis and quality control.

CellAssist — Breaks down common time rapidly requires and reduces images and automates culture process. More importantly, Thrive's products provide insight by building a database of cell, and culture images and metadata as growth, cell differentiation and maturation. The system also documents cell culture laboratory processes and inputs and provides real-time analysis.

CellAssist 50 — Breaks down common time rapidly requires and reduces images and automates culture process. More importantly, Thrive's products provide insight by building a database of cell, and culture images and metadata as growth, cell differentiation and maturation. The system also documents cell culture laboratory processes and inputs and provides real-time analysis.

Full Automation — Breaks down common time rapidly requires and reduces images and automates culture process. More importantly, Thrive's products provide insight by building a database of cell, and culture images and metadata as growth, cell differentiation and maturation. The system also documents cell culture laboratory processes and inputs and provides real-time analysis.

Good science needs good cells

Thrive Bioscience, Inc. 22 Columbia St. #1000 Boston, MA 02114
Phone: 617.252.1000 | Email: info@thrivescience.com | Website: www.thrivescience.com

Dedicated Page Example